The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Tumour-targeted nanomedicines: principles and practice
Open accessAbstract
Drug targeting systems are nanometre-sized carrier materials designed for improving the biodistribution of systemically applied (chemo)therapeutics. Various different tumour-targeted nanomedicines have been evaluated over the years, and clear evidence is currently available for substantial improvement of the therapeutic index of anticancer agents. Here, we briefly summarise the most important targeting systems and strategies, and discuss recent advances and future directions in the development of tumour-targeted nanomedicines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565 · cited 1×
“The exploitation of this so-called ‘enhanced permeability and retention’ (EPR) effect is currently the most important strategy for improving the delivery of low-molecular-weight (chemo)therapeutic agents to tumours (Maeda et al, 2000; Torchilin, 2005; Duncan, 2006).”
BackgroundRecent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Diffusion of univalent ions across the lamellae of swollen phospholipids
Bangham, A. D., Standish, M. M., & Watkins, J. C. (1965) · Journal of Molecular Biology · doi:10.1016/s0022-2836(65)80093-6 · Cited by 4,664
Gradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Hawkins, M., & O'Shaughnessy, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.937 · Cited by 2,153
Polymer conjugates as anticancer nanomedicines
Duncan, R. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1958 · Cited by 1,962
Ligand-targeted therapeutics in anticancer therapy
Allen, T. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc903 · Cited by 1,647
Optimizing Liposomes for Delivery of Chemotherapeutic Agents to Solid Tumors
Drummond, D. C., Meyer, O., Hong, K., Kirpotin, D. B., & Papahadjopoulos, D. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01426-1 · Cited by 1,263
Kirpotin, D. B., Drummond, D. C., Shao, Y., Shalaby, M. R., Hong, K., Nielsen, U. B., Marks, J. D., Benz, C. C., & Park, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4199 · Cited by 1,125
Structure and properties of pharmacologically active polymers
Ringsdorf, H. (1975) · Journal of Polymer Science: Polymer Symposia · doi:10.1002/polc.5070510111 · Cited by 1,094 · cited 1×
“Conceptualised by Ringsdorf (1975), it was envisioned that polymeric macromolecules can be conjugated to pharmacologically active agents by means of linkers that are stable in blood, but labile in the acidic and/or enzymatic conditions typical of, for example, the tumour microenvironment or certain…”
Background
Cited by
Danhier, F., Feron, O., & Préat, V. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.08.027 · Cited by 2,800
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation
Kamaly, N., Xiao, Z., Valencia, P. M., Radovic-Moreno, A. F., & Farokhzad, O. C. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15344k · Cited by 1,730
Sapsford, K. E., Algar, W. R., Berti, L., Gemmill, K. B., Casey, B. J., Oh, E., Stewart, M. H., & Medintz, I. L. (2013) · Chemical Reviews · doi:10.1021/cr300143v · Cited by 1,423
Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress
Lammers, T., Kiessling, F., Hennink, W. E., & Storm, G. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.063 · Cited by 1,324
Self-citationBlock copolymer micelles in nanomedicine applications
Cabral, H., Miyata, K., Osada, K., & Kataoka, K. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00199 · Cited by 1,309
Challenges in Development of Nanoparticle-Based Therapeutics
Desai, N. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9339-4 · Cited by 1,173
Attia, M. F., Anton, N., Wallyn, J., Omran, Z., & Vandamme, T. F. (2019) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.13098 · Cited by 1,085
Nanomedicine(s) under the Microscope
Duncan, R., & Gaspar, R. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200394t · Cited by 981
Targeting nanoparticles to cancer
Wang, M., & Thanou, M. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.03.005 · Cited by 931
Dai, Y., Xu, C., Sun, X., & Chen, X. (2017) · Chemical Society Reviews · doi:10.1039/c6cs00592f · Cited by 931
Nanomaterials: Applications in Cancer Imaging and Therapy
Barreto, J. A., O’Malley, W., Kubeil, M., Graham, B., Stephan, H., & Spiccia, L. (2011) · Advanced Materials · doi:10.1002/adma.201100140 · Cited by 907
Lammers, T., Aime, S., Hennink, W. E., Storm, G., & Kiessling, F. (2011) · Accounts of Chemical Research · doi:10.1021/ar200019c · Cited by 870
Self-citationYeh, M.-K., Chang, H.-I., & Cheng, M.-Y. (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s26766 · Cited by 801
The therapeutic potential of nanobodies
Jovčevska, I., & Muyldermans, S. (2020) · BioDrugs · doi:10.1007/s40259-019-00392-z · Cited by 749
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come
Yingchoncharoen, P., Kalinowski, D. S., & Richardson, D. R. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.012070 · Cited by 744
Shen, Y., Jin, E., Zhang, B., Murphy, C. J., Sui, M., Zhao, J., Wang, J., Tang, J., Fan, M., Van Kirk, E., et al. (2010) · Journal of the American Chemical Society · doi:10.1021/ja909475m · Cited by 565
PLGA-Based Nanoparticles as Cancer Drug Delivery Systems
Tabatabaei Mirakabad, F. S., Nejati-Koshki, K., Akbarzadeh, A., Yamchi, M. R., Milani, M., Zarghami, N., Zeighamian, V., Rahimzadeh, A., Alimohammadi, S., Hanifehpour, Y., et al. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.2.517 · Cited by 542
Nanotheranostics for personalized medicine
Mura, S., & Couvreur, P. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.06.006 · Cited by 527
Protein‐Based Nanomedicine Platforms for Drug Delivery
MaHam, A., Tang, Z., Wu, H., Wang, J., & Lin, Y. (2009) · Small · doi:10.1002/smll.200801602 · Cited by 524
Lindsey, B. A., Markel, J. E., & Kleinerman, E. S. (2017) · Rheumatology and Therapy · doi:10.1007/s40744-016-0050-2 · Cited by 487
Gidwani, B., & Vyas, A. (2015) · BioMed Research International · doi:10.1155/2015/198268 · Cited by 473
Delivery of chemotherapeutic drugs in tumour cell-derived microparticles
Tang, K., Zhang, Y., Zhang, H., Xu, P., Liu, J., Ma, J., Lv, M., Li, D., Katirai, F., Shen, G.-X., et al. (2012) · Nature Communications · doi:10.1038/ncomms2282 · Cited by 453
Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents
Dinarvand, R., Sepehri, N., Manouchehri, Rouhani, & Atyabi, F. (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s18905 · Cited by 453
Polymeric nanoparticles for targeted treatment in oncology: current insights
Joshi, M. D., Patravale, V., & Prabhu, R. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s56932 · Cited by 438
Barz, M., Luxenhofer, R., Zentel, R., & Vicent, M. J. (2011) · Polymer Chemistry · doi:10.1039/c0py00406e · Cited by 418
Human and environmental impacts of nanoparticles: a scoping review of the current literature
Kumah, E. A., Fopa, R. D., Harati, S., Boadu, P., Zohoori, F. V., & Pak, T. (2023) · BMC Public Health · doi:10.1186/s12889-023-15958-4 · Cited by 411
Nanotheranostics and image-guided drug delivery: current concepts and future directions
Lammers, T., Kiessling, F., Hennink, W. E., & Storm, G. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100228v · Cited by 397
Self-citationBreast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and Technologies
Nounou, M. I., ElAmrawy, F., Ahmed, N., Abdelraouf, K., Goda, S., & Syed-Sha-Qhattal, H. (2015) · Breast Cancer: Basic and Clinical Research · doi:10.4137/bcbcr.s29420 · Cited by 364
Nanotechnology-based approaches in anticancer research
Kamal, M. A., Jabir NR, N., Tabrez, Ashraf, Shakil, & Damanhouri (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s33838 · Cited by 363
Review on Micro- and Nanolithography Techniques and their Applications
Pimpin, A., & Srituravanich, W. (2012) · Engineering Journal · doi:10.4186/ej.2012.16.1.37 · Cited by 363
Heparin-functionalized polymeric biomaterials in tissue engineering and drug delivery applications
Liang, Y., & Kiick, K. L. (2014) · Acta Biomaterialia · doi:10.1016/j.actbio.2013.07.031 · Cited by 349
The evolving landscape of drug products containing nanomaterials in the United States
D'Mello, S. R., Cruz, C. N., Chen, M.-L., Kapoor, M., Lee, S. L., & Tyner, K. M. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.67 · Cited by 345
Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications
Rizzo, L. Y., Theek, B., Storm, G., Kiessling, F., & Lammers, T. (2013) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2013.02.020 · Cited by 336
Self-citationPh-responsive polymer–drug conjugates: design and progress
Pang, X., Jiang, Y., Xiao, Q., Leung, A. W., Hua, H., & Xu, C. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.12.024 · Cited by 317
Passive versus Active Tumor Targeting Using RGD- and NGR-Modified Polymeric Nanomedicines
Kunjachan, S., Pola, R., Gremse, F., Theek, B., Ehling, J., Moeckel, D., Hermanns-Sachweh, B., Pechar, M., Ulbrich, K., Hennink, W. E., et al. (2014) · Nano Letters · doi:10.1021/nl404391r · Cited by 317
Self-citationCharge‐Reversal Drug Conjugate for Targeted Cancer Cell Nuclear Drug Delivery
Zhou, Z., Shen, Y., Tang, J., Fan, M., Van Kirk, E. A., Murdoch, W. J., & Radosz, M. (2009) · Advanced Functional Materials · doi:10.1002/adfm.200900825 · Cited by 311
Liposome-based drug co-delivery systems in cancer cells
Zununi Vahed, S., Salehi, R., Davaran, S., & Sharifi, S. (2017) · Materials Science and Engineering: C · doi:10.1016/j.msec.2016.11.073 · Cited by 307
Nanopreparations for organelle-specific delivery in cancer
Biswas, S., & Torchilin, V. P. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.004 · Cited by 292
Lammers, T. (2024) · Advanced Materials · doi:10.1002/adma.202312169 · Cited by 290
Self-citationChang, B., Sha, X., Guo, J., Jiao, Y., Wang, C., & Yang, W. (2011) · Journal of Materials Chemistry · doi:10.1039/c1jm10631g · Cited by 273
Doxorubicin-loaded glycyrrhetinic acid-modified alginate nanoparticles for liver tumor chemotherapy
Zhang, C., Wang, W., Liu, T., Wu, Y., Guo, H., Wang, P., Tian, Q., Wang, Y., & Yuan, Z. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2011.11.045 · Cited by 268
Core-crosslinked polymeric micelles with controlled release of covalently entrapped doxorubicin
Talelli, M., Iman, M., Varkouhi, A. K., Rijcken, C. J. F., Schiffelers, R. M., Etrych, T., Ulbrich, K., van Nostrum, C. F., Lammers, T., Storm, G., et al. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.07.005 · Cited by 267
Self-citationSynergistic nanomedicine by combined gene and photothermal therapy
Kim, J., Kim, J., Jeong, C., & Kim, W. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.12.018 · Cited by 262
Multidrug resistance: Physiological principles and nanomedical solutions
Kunjachan, S., Rychlik, B., Storm, G., Kiessling, F., & Lammers, T. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.018 · Cited by 259
Self-citationEvolution in Lithography Techniques: Microlithography to Nanolithography
Sharma, E., Rathi, R., Misharwal, J., Sinhmar, B., Kumari, S., Dalal, J., & Kumar, A. (2022) · Nanomaterials · doi:10.3390/nano12162754 · Cited by 257
Talelli, M., Rijcken, C. J. F., Lammers, T., Seevinck, P. R., Storm, G., van Nostrum, C. F., & Hennink, W. E. (2009) · Langmuir · doi:10.1021/la8036499 · Cited by 210
Self-citationRecent Advances in Nanomicelles Delivery Systems.
Tawfik, S. M., Azizov, S., Elmasry, M. R., Sharipov, M., & Lee, Y.-I. (2020) · Nanomaterials · doi:10.3390/nano11010070 · Cited by 156
iRGD Peptide as a Tumor-Penetrating Enhancer for Tumor-Targeted Drug Delivery
Kang, S., Lee, S., & Park, S. (2020) · Polymers · doi:10.3390/polym12091906 · Cited by 139
Iron oxide-loaded nanotheranostics: major obstacles to in vivo studies and clinical translation
Schleich, N., Danhier, F., & Préat, V. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.11.024 · Cited by 124
“However, because targeted nanomedicines have no means of self-propulsion, reaching the target site and subsequently accumulating in the tumor tissue, relies on EPRmediated extravasation, which has several disadvantages as outlined above [53,80].”
BackgroundKuai, R., Yuan, W., Li, W., Qin, Y., Tang, J., Yuan, M., Fu, L., Ran, R., Zhang, Z., & He, Q. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200100f · Cited by 76
de Maar, J. S., Sofias, A. M., Porta Siegel, T., Vreeken, R. J., Moonen, C., Bos, C., & Deckers, R. (2020) · Theranostics · doi:10.7150/thno.38625 · Cited by 71
Wang, X., Liu, B., Xu, Q., Sun, H., Shi, M., Wang, D., Guo, M., Yu, J., Zhao, C., & Feng, B. (2017) · Wound Repair and Regeneration · doi:10.1111/wrr.12520 · Cited by 54
Wang, T., Yang, S., Mei, L. A., Parmar, C. K., Gillespie, J. W., Praveen, K. P., Petrenko, V. A., & Torchilin, V. P. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0052 · Cited by 35
“normal tissues, and only a small fraction of the injected doses deposits at tumor sites (1).”
Background
Metadata
- Authors
- Lammers, T., Hennink, W. E., & Storm, G.
- Venue
- British Journal of Cancer
- Published
- 2008-07-22
- Volume
- 99
- Issue
- 3
- Pages
- 392-397
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2004109893
- Cited by
- 542
- References
- 31
- FWCI
- 17.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.